Virpax and Nanomerics Enter Technology License Agreement for Developing A Product for PTSD Treatment

2020-02-24
Virpax® Pharmaceuticals Inc., a USA-based company specializing in the development of innovative drug delivery systems, has recently signed an agreement with Nanomerics Ltd., a company recognized for its world-leading expertise in pharmaceutical nanotechnology, to license Nanomerics' Molecular Envelope Technology (MET) for the development of a new product that enables the exclusive delivery of a metabolically labile intranasal peptide into the brain for treating Post-Traumatic Stress Disorder (PTSD).

Virpax® Pharmaceuticals Inc. ("Virpax"), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, signed a technology license agreement with Nanomerics Ltd.

Under the agreement, Virpax has exclusive global rights to use Nanomerics' nanotechnology for the delivery of a metabolically labile intranasal peptide for the management of Post-Traumatic Stress Disorder (PTSD). PES200 will be the second investigational product formulation delivered via the nasal route to enhance enkephalin transport to the brain developed by Virpax. PES200 will use a preassembled device and cartridge to propel the enkephalin formulation through the nose to the brain via the olfactory nerve.

In theory, the Molecular Envelope Technology (MET) will help to carry the enkephalin to the brain to suppress anxiety. Virpax and Nanomerics will validate proof-of-concept followed by IND-enabling studies for the development of its novel enkephalin-based formulation to treat Post-Traumatic Stress Disorder. Virpax has exclusive global rights to the proprietary MET Intranasal enkephalin delivery technology for pain management and PTSD.

"We are delighted to be collaborating with Virpax Pharmaceuticals in the development of a product to treat PTSD," said Nanomerics' Chief Scientific Officer, Professor Ijeoma F. Uchegbu. "We look forward to working with Virpax to bring these innovative new treatments to patients."

Read the original article on Accesswire.